Braidwell LP Ironwood Pharmaceuticals Inc Transaction History

Braidwell LP

  • $1.63 Billion
  • Q2 2025

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025
BUY
$1.41 - $4.58 $1.67 Million - $5.41 Million
1,182,307 Added 21.73%
6,622,584 $9.74 Million
Q4 2024

Feb 14, 2025
BUY
$3.34 - $5.04 $3.35 Million - $5.05 Million
1,002,045 Added 22.58%
5,440,277 $24.1 Million
Q2 2024

Aug 14, 2024
BUY
$5.58 - $8.61 $5.29 Million - $8.17 Million
948,389 Added 27.18%
4,438,232 $28.9 Billion
Q1 2024

May 15, 2024
BUY
$8.32 - $15.45 $29 Million - $53.9 Million
3,489,843 New
3,489,843 $30.4 Billion
Q3 2023

Nov 14, 2023
BUY
$8.25 - $11.35 $11.1 Million - $15.3 Million
1,348,099 New
1,348,099 $13 Billion

Others Institutions Holding IRWD

# of Institutions
178
Shares Held
169M
Call Options Held
11.2M
Put Options Held
0
View Full List

About IRONWOOD PHARMACEUTICALS INC

IRWD Quotes by TradingView
  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $150M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Braidwell LP Portfolio

Follow Braidwell LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email